Evommune CEO sells 16,787 shares in open market

Evommune, Inc. President & CEO Luis C. Pena reported an open-market sale of common stock.

Rhea-AI Filing Summary

Evommune, Inc. President & CEO Luis C. Pena reported an open-market sale of common stock. On June 1, 2026, he sold 16,787 shares of Evommune common stock at a weighted average price of $22.74 per share in multiple transactions. These trades were made pursuant to a pre-arranged Rule 10b5-1 trading plan. After the sale, Pena directly holds 637,896 shares of Evommune common stock.

Insider Trade Summary 10b5-1

Net Seller: 16,787 shares

Net Sell 1 txn

Insider Pena Luis C.

Role President & CEO

Sold 16,787 shs ($382K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,787	$22.74	$382K

Holdings After Transaction: Common Stock — 637,896 shares (Direct)

Footnotes (2)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 16,787 shares Weighted average sale price: $22.74 per share Post-transaction holdings: 637,896 shares +1 more

4 metrics

Shares sold 16,787 shares Open-market sale of common stock on June 1, 2026

Weighted average sale price $22.74 per share Common stock sale on June 1, 2026

Post-transaction holdings 637,896 shares Direct ownership after June 1, 2026 sale

Price range of trades $22.50–$23.34 per share Range for multiple executions included in the sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Evommune (EVMN) CEO Luis C. Pena report?

Evommune President & CEO Luis C. Pena reported an open-market sale of 16,787 shares of common stock. The Form 4 shows this was a planned transaction executed under a Rule 10b5-1 trading plan, rather than a discretionary one-time trade.

When did the Evommune (EVMN) CEO’s latest stock sale occur?

The stock sale by Evommune CEO Luis C. Pena occurred on June 1, 2026. This date is listed as the transaction date on the Form 4 and applies to the full 16,787-share open-market sale of common stock reported.

How many Evommune (EVMN) shares did the CEO sell and at what price?

Luis C. Pena sold 16,787 shares of Evommune common stock at a weighted average price of $22.74 per share. The filing notes multiple trade executions within a price range from $22.50 to $23.34 inclusive on the transaction date.

How many Evommune (EVMN) shares does the CEO hold after this sale?

Following the June 1, 2026 transaction, Luis C. Pena directly holds 637,896 shares of Evommune common stock. This post-transaction figure is disclosed in the Form 4 and reflects his remaining direct ownership after the 16,787-share sale.

Was the Evommune (EVMN) CEO’s stock sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the transactions were executed under a Rule 10b5-1 trading plan adopted on March 2, 2026. Such plans are pre-arranged trading programs that schedule trades in advance, reducing the role of day-to-day discretion.

What does the weighted average price mean in the Evommune (EVMN) Form 4?

The reported $22.74 weighted average price reflects multiple trade executions between $22.50 and $23.34. The filing explains that individual trades occurred at different prices within this range and that detailed breakdowns are available to investors upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 08:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pena Luis C.

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		16,787	D	$22.74(2)	637,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)